Pembrolizumab vs. other PD‑1 inhibitors – what the data say
| Drug | Key clinical trials (phase III) | Tumor indications (first‑line or beyond) | Typical ORR (overall response rate) | Median OS (overall survival) | Notable safety signals |
|------|---------------------------------|-------------------------------------------|-----------------------------------|------------------------------|------------------------|
| Pembrolizumab | KEYNOTE‑024, KEYNOTE‑042, KEYNOTE‑001, KEYNOTE‑189, KEYNOTE‑407, KEYNOTE‑170 (NSCLC, gastric, melanoma, HCC, etc.) | • 1st‑line in metastatic NSCLC with PD‑L1 ≥ 50% (KEYNOTE‑024)
• 1st‑line in MSI‑high / TMB‑high cancers (all‑solid)
• 2nd‑line or beyond in many cancers | ~40–45 % in NSCLC (PD‑L1 ≥ 50%), ~25 % in gastric, ~30 % in melanoma, ~20 % in MSI‑high CRC | 17–20 mo in NSCLC (1st‑line), 17 mo in MSI‑high CRC, 9–11 mo in gastric | Immune‑related AEs (rash, colitis, pneumonitis); rare endocrine events |
| Nivolumab | CheckMate 057 (renal cell), CheckMate 017/059 (NSCLC), CheckMate 227 (NSCLC), CheckMate 078 (HCC) | • 2nd‑line in metastatic NSCLC (≥ 50 % PD‑L1)
• 1st‑line in RCC
• 2nd‑line in HCC | ~20–30 % in NSCLC (≥ 50 % PD‑L1), ~26 % in RCC, ~22 % in HCC | 14–18 mo in NSCLC, 31 mo in RCC, 8 mo in HCC | Similar to pembrolizumab; slight uptick in skin toxicities |
| Cemiplimab | EMPOWER‑CT‑01 (BCC), EMPOWER‑CR‑01 (skin SCC) | • 1st‑line or 2nd‑line BCC / SCC | ~50–70 % (BCC), ~40 % (SCC) | 12–15 mo (BCC), 9 mo (SCC) | Generally well tolerated; similar endocrine profile |
| Dostarlimab | GARNET (endometrial) | • 1st‑line in MSI‑high endometrial cancer | ~50 % | 24 mo | Similar immune‑related AEs |
---
1. Head‑to‑Head Evidence (Direct Comparisons)
* Pembrolizumab vs. Nivolumab in NSCLC
– No large, randomized, direct‑comparison trials yet.
– Indirect evidence (network meta‑analysis of 28 trials) suggests no statistically significant difference in ORR, PFS or OS across most indications.
* Pembrolizumab vs. Cemiplimab
– Only indirect data from separate trials; efficacy appears comparable in cutaneous tumors, but cemiplimab shows higher ORR in BCC due to its specific FDA indication.
* Pembrolizumab vs. Dostarlimab
– GARNET (dostarlimab) and KEYNOTE‑158 (pembrolizumab) used in MSI‑high tumors show similar ORR (~50 %) but dostarlimab’s trial had slightly higher OS at 12 months; however, populations differ.
---
2. Biomarker‑Driven Differences
| Biomarker | Pembrolizumab advantage | Nivolumab advantage |
|-----------|------------------------|---------------------|
| PD‑L1 TPS ≥ 50 % in NSCLC | First‑line OS benefit (KEYNOTE‑024) | 2nd‑line benefit (CheckMate 057) |
| MSI‑high / dMMR | FDA‑approved first‑line across all solid tumors | Approved after 2019, but pembrolizumab remains first‑in‑class |
| TMB‑high (> 10 mut/Mb) | Pembrolizumab 1st‑line in select cases (KEYNOTE‑158) | Similar data emerging for nivolumab but less robust |
Bottom line: PD‑1 inhibitors are largely interchangeable within the same tumor type and biomarker profile. Differences become clinically relevant mainly when specific regulatory approvals or insurance coverages dictate drug choice.
---
3. Efficacy Nuances
1. Response Duration
- Pembrolizumab has demonstrated a long‑lasting response in a subset of patients (median duration > 2 years in NSCLC), similar to nivolumab.
2. Survival Benefit
- In KEYNOTE‑042 (NSCLC), pembrolizumab improved OS vs. chemotherapy in patients with PD‑L1 ≥ 1 % (median OS 13.9 mo vs 11.2 mo).
- CheckMate 227 (NSCLC) showed a modest OS improvement with nivolumab + ipilimumab vs chemotherapy in PD‑L1 ≥ 1 %, but no significant benefit for nivolumab alone.
3. Combination Therapies
- Pembrolizumab + chemo (KEYNOTE‑189, KEYNOTE‑407) outperforms chemo alone in non‑small‑cell lung cancer and squamous NSCLC.
- Nivolumab + ipilimumab (CheckMate 227) offers a different safety profile and may be preferable in patients with lower PD‑L1 expression.
---
4. Safety Profile
| AE | Pembrolizumab | Nivolumab | Cemiplimab | Dostarlimab |
|----|---------------|-----------|------------|-------------|
| Dermatologic (rash, pruritus) | ~15 % | ~12 % | ~10 % | ~9 % |
| Colitis | ~5 % | ~6 % | ~4 % | ~3 % |
| Pneumonitis | ~4 % | ~5 % | ~3 % | ~3 % |
| Endocrine | 3–4 % | 2–3 % | 1–2 % | 1–2 % |
| Severe (grade ≥ 3) | ~5 % | ~5 % | ~4 % | ~3 % |
Key point: Safety profiles are broadly similar; slight variations exist, but clinical decision‑making usually hinges on efficacy, cost, and patient preference rather than safety alone.
---
5. Practical Take‑Home Messages
1. Within a given cancer and biomarker (e.g., metastatic NSCLC with PD‑L1 ≥ 50 % or MSI‑high CRC), pembrolizumab and nivolumab provide comparable response rates, PFS, and OS.
2. Pembrolizumab holds a first‑line advantage in NSCLC with high PD‑L1 and in all MSI‑high/dMMR solid tumors, thanks to its earlier FDA approvals.
3. Cost and insurance coverage often drive drug choice. Some payers prefer one over the other based on formulary status or negotiated discounts.
4. **If a patient has a specific biomarker (